This study will evaluate whether commonly used blood pressure medications called "ACE inhibitors" can lower parathyroid hormone.
The RAAS-PARC study will evaluate whether angiotensin-converting enzyme inhibitors (ACEi) can lower parathyroid hormone (PTH) in normal controls and in individuals have a diagnosis of primary hyperparathyroidism. Emerging data has implicated the renin-angiotensin-aldosterone system (RAAS) activity with increased PTH. The principal investigator, and other investigators, have previously shown that inhibiting the RAAS may lower PTH. The current study will focus on: 1. Normal Physiology: Does an ACEi (which lowers angiotensin II and aldosterone) reduce PTH in normal individuals? 2. Pathophysiology: Does an ACEi reduce PTH in individuals with primary hyperparathyroidism? The results of this study may have important implications for cardiovascular and skeletal health, as both the RAAS and PTH have been implicated as mediators of these conditions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
41
Each subject will receive one week of lisinopril and return for repeat for blood measurements.
Brigham and Women's Hospital
Boston, Massachusetts, United States
Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration
PTH values 1 week following ACE inhibitor therapy
Time frame: 1 week
Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy
Time frame: 1 week
Serum Calcium Following 1 Week of ACE Inhibitor Administration
Time frame: 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.